Название продукции:Lithium(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carboxylate
IUPAC Name:(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carboxylic acid lithium
- CAS:2864383-31-1
- Молекулярная формула:C7H11LiNO2
- Чистота:95%+
- Номер в каталоге:CM1048983
- Молекулярная масса:148.11
Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:2864383-31-1
- Молекулярная формула:C7H11LiNO2
- Точка плавления:-
- Smiles-код:C(O)(=O)[C@H]1[C@H](N1C)C2CC2.[Li]
- Плотность:
- Номер в каталоге:CM1048983
- Молекулярная масса:148.11
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Aziridines
- Aziridines are highly strained three-membered heterocyclic molecules composed of one amine group and two carbon units. They are aza analogs of epoxides. Aziridines are a very important class of synthetic building blocks and intermediates in organic synthesis, which are widely used in organic synthesis, especially in the synthesis of nitrogen-containing natural products. Due to the high ring tension of aziridine, its reactivity is high. Under certain conditions, it can undergo cycloaddition reaction with various dipolar reagents to prepare some new nitrogen-containing heterocyclic compounds.
- Aziridines are a very important class of synthetic building blocks and intermediates in organic synthesis
- Aziridines,
- Aziridines are highly strained three-membered heterocyclic molecules composed of one amine group and two carbon units. They are aza analogs of epoxides.
Column Infos
- RMC-9805
- Revolution Medicines announced preliminary positive data for its RAS(ON) G12D-selective covalent inhibitor RMC-9805 in previously treated pancreatic ductal adenocarcinoma (PDAC) patients. The analysis showed that the disease control rate of PDAC patients treated with RMC-9805 was as high as 80%. RMC-9805 is a potential ‘first-in-class’ oral RAS(ON) G12D-selective inhibitor, that is being evaluated in trials to examine its efficacy and safety in patients with solid tumors carrying KRAS G12D mutations when used as a single agent or in combination with the pan-RAS inhibitor RMC-6236.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.